One trial evaluated TB4 for heart health, finding that the peptide could protect and repair the heart in patients with acute myocardial infarction, and a separate trial found that TB4 improved outcomes during congenital heart surgery.21 The review also mentions a few clinical trials related to eye health, with results showing that TB4 can reduce eye dryness, relieve ocular discomfort, lower inflammation in the conjunctiva, and more
[12] So far, NAD+ therapy has been used alongside standard treatments (like antidepressants, for example) without incident
It is essential to be clear: the human safety data for injectable, oral, or high-dose systemic GHK-Cu is essentially absent
BPC-157 is classified as a Category 2 bulk drug substance as of April 2026, meaning it is prohibited in compounding under Section 503A and 503B
What are the benefits of administering DSIP through a nasal spray
At therapeutic GHK-Cu doses, copper accumulation is not a clinical concern for healthy individuals but it is why medical oversight matters